CoChat

Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8 + T cells

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Objective: Roseburia intestinalis is a probiotic species that can suppress intestinal inflammation by producing metabolites. We aimed to study the role of R. intestinalis in colorectal tumourigenesis and immunotherapy. Design: R. intestinalis abundance was evaluated in stools of patients with colorectal cancer (CRC) (n=444) and healthy controls (n=575). The effects of R. intestinalis were studied in Apc Min/+ or azoxymethane (AOM)-induced CRC mouse models, and in syngeneic mouse xenograft models of CT26 (microsatellite instability (MSI)-low) or MC38 (MSI-high). The change of immune landscape was evaluated by multicolour flow cytometry and immunohistochemistry staining. Metabolites were profiled by metabolomic profiling. Results: R. intestinalis was significantly depleted in stools of patients with CRC compared with healthy controls. R. intestinalis administration significantly inhibited tumour formation in Apc Min/+ mice, which was confirmed in mice with AOM-induced CRC. R. intestinalis restored gut barrier function as indicated by improved intestinal permeability and enhanced expression of tight junction proteins. Butyrate was identified as the functional metabolite generated by R. intestinalis. R. intestinalis or butyrate suppressed tumour growth by inducing cytotoxic granzyme B + , interferon (IFN)-γ + and tumour necrosis factor (TNF)-α + CD8 + T cells in orthotopic mouse models of MC38 or CT26. R. intestinalis or butyrate also significantly improved antiprogrammed cell death protein 1 (anti-PD-1) efficacy in mice bearing MSI-low CT26 tumours. Mechanistically, butyrate directly bound to toll-like receptor 5 (TLR5) receptor on CD8 + T cells to induce its activity through activating nuclear factor kappa B (NF-κB) signalling. Conclusion: R. intestinalis protects against colorectal tumourigenesis by producing butyrate, which could also improve anti-PD-1 efficacy by inducing functional CD8 + T cells. R. intestinalis is a potential adjuvant to augment anti-PD-1 efficacy against CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2023-330291

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Roseburia intestinalis (R.i) reduces colorectal carcinogenesis in ApcMin/+ and azoxymethane (AOM)-induced mice. (A) Schematic diagram showing the experimental design and timeline of ApcMin/+ mice experiment. (B) Representative colonic morphologies (left panel) and colonoscopy video captures (right panel) of ApcMin/+ mice. Colon tumour incidence (C), colon tumour number and colon tumour load (total tumour area, mm2) (D) of ApcMin/+ mice. (E) Representative H&E staining images (scale bar=200 µm) and Ki-67 immunohistochemistry (IHC) staining (scale bar=50 µm) of ApcMin/+ mice. (F) Schematic diagram showing the experimental design and timeline of AOM-induced mice. (G) Representative colonic morphologies (left panel) and colonoscopy video captures and incidence (right panel) of AOM-induced mice. Colon tumour incidence (H), colon tumour number and colon tumour load (total tumour area, mm2) (I) of AOM-induced mice. (J) Representative H&E staining images (scale bar=200 µm) and Ki-67 IHC staining (scale bar=50 µm) of AOM-induced mice. Con, control; E. coli; Escherichia coli; PBS, phosphate-buffered saline.
Figure 1 Roseburia intestinalis (R.i) reduces colorectal carcinogenesis in ApcMin/+ and azoxymethane (AOM)-induced mice. (A) Schematic diagram showing the experimental design and timeline of ApcMin/+ mice experiment. (B) Representative colonic morphologies (left panel) and colonoscopy video captures (right panel) of ApcMin/+ mice. Colon tumour incidence (C), colon tumour number and colon tumour load (total tumour area, mm2) (D) of ApcMin/+ mice. (E) Representative H&E staining images (scale bar=200 µm) and Ki-67 immunohistochemistry (IHC) staining (scale bar=50 µm) of ApcMin/+ mice. (F) Schematic diagram showing the experimental design and timeline of AOM-induced mice. (G) Representative colonic morphologies (left panel) and colonoscopy video captures and incidence (right panel) of AOM-induced mice. Colon tumour incidence (H), colon tumour number and colon tumour load (total tumour area, mm2) (I) of AOM-induced mice. (J) Representative H&E staining images (scale bar=200 µm) and Ki-67 IHC staining (scale bar=50 µm) of AOM-induced mice. Con, control; E. coli; Escherichia coli; PBS, phosphate-buffered saline.CC BY-NC · PubMed Central
Figure 2 Roseburia intestinalis (R.i) enhances epithelial barrier functions in ApcMin/+ mice. (A) FITC-dextran (4 kDa) concentration (ng/mL) in ApcMin/+ mice serum. (B) Expression levels of tight junction proteins ZO-1 and claudin-3 determined by western blot analysis in colon tissues of ApcMin/+ mice. (C) Representative ZO-1 and claudin-3 immunohistochemistry staining images (scale bar=50 µm). Con, control; E. coli, Escherichia coli; FITC, fluorescein isothiocyanate; ZO-1, zonula occludens-1.
Figure 2 Roseburia intestinalis (R.i) enhances epithelial barrier functions in ApcMin/+ mice. (A) FITC-dextran (4 kDa) concentration (ng/mL) in ApcMin/+ mice serum. (B) Expression levels of tight junction proteins ZO-1 and claudin-3 determined by western blot analysis in colon tissues of ApcMin/+ mice. (C) Representative ZO-1 and claudin-3 immunohistochemistry staining images (scale bar=50 µm). Con, control; E. coli, Escherichia coli; FITC, fluorescein isothiocyanate; ZO-1, zonula occludens-1.CC BY-NC · PubMed Central
Figure 3 Roseburia intestinalis cultured medium (R.i CM) exhibits tumour-suppressive effects in vitro. (A) R.i CM (5%) reduced the colonic cell viability, except NCM460. Escherichia coli conditioned medium (E. coli CM) and yeast casitone fatty acids broth (YCFA) were used as control. (B) R.i CM (5%) suppressed the colony formation of colorectal cancer (CRC) cells. (C) R.i CM reduced CRC cell Ki-67 expression levels determined by immunocytochemistry. (D) R.i CM increased CRC cell apoptosis. (E) R.i CM induced CRC cell apoptosis of CRC cells by cleaved caspase-3, cleaved caspase-7, cleaved caspase-9 and cleaved poly (ADP-ribose) polymerase (PARP) expression. (F) R.i CM inhibited CRC cell cycle G1/S transition. (G) R.i CM induced G1 arrest by Cdk6 downregulation and p27 Kip1 upregulation. (H) R.i CM inhibited the growth of the organoid derived from a patient with CRC.
Figure 3 Roseburia intestinalis cultured medium (R.i CM) exhibits tumour-suppressive effects in vitro. (A) R.i CM (5%) reduced the colonic cell viability, except NCM460. Escherichia coli conditioned medium (E. coli CM) and yeast casitone fatty acids broth (YCFA) were used as control. (B) R.i CM (5%) suppressed the colony formation of colorectal cancer (CRC) cells. (C) R.i CM reduced CRC cell Ki-67 expression levels determined by immunocytochemistry. (D) R.i CM increased CRC cell apoptosis. (E) R.i CM induced CRC cell apoptosis of CRC cells by cleaved caspase-3, cleaved caspase-7, cleaved caspase-9 and cleaved poly (ADP-ribose) polymerase (PARP) expression. (F) R.i CM inhibited CRC cell cycle G1/S transition. (G) R.i CM induced G1 arrest by Cdk6 downregulation and p27 Kip1 upregulation. (H) R.i CM inhibited the growth of the organoid derived from a patient with CRC.CC BY-NC · PubMed Central
Figure 4 The tumour-suppressive component produced by Roseburia intestinalis is butyric acid. (A) The efficient components in R. intestinalis cultured medium (R.i CM) are <3 kDa. (B) The R.i CM <3 kDa fraction was assessed by untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis and butyric acid was identified as the candidate tumour-suppressive molecule. (C) Butyrate acid concentration (µg/mL) in R.i CM <3 kDa was determined by targeted short chain fatty acid gas chromatography-mass spectrometry (GC-MS) analysis. (D) Relative concentration of butyrate acid (area under curve (AUC)) in ApcMin/+ and azoxymethane (AOM)-induced mice faeces was determined by GC-MS analysis. (E) Comparable dosage (1 mM) of butyrate in R.i CM reduced the colonic cell viability, except NCM460. (F) Butyrate-induced colorectal cancer (CRC) cell apoptosis. (G) Butyrate inhibited CRC cell cycle G1/S transition. Con, control; E. coli, Escherichia coli.
Figure 4 The tumour-suppressive component produced by Roseburia intestinalis is butyric acid. (A) The efficient components in R. intestinalis cultured medium (R.i CM) are <3 kDa. (B) The R.i CM <3 kDa fraction was assessed by untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis and butyric acid was identified as the candidate tumour-suppressive molecule. (C) Butyrate acid concentration (µg/mL) in R.i CM <3 kDa was determined by targeted short chain fatty acid gas chromatography-mass spectrometry (GC-MS) analysis. (D) Relative concentration of butyrate acid (area under curve (AUC)) in ApcMin/+ and azoxymethane (AOM)-induced mice faeces was determined by GC-MS analysis. (E) Comparable dosage (1 mM) of butyrate in R.i CM reduced the colonic cell viability, except NCM460. (F) Butyrate-induced colorectal cancer (CRC) cell apoptosis. (G) Butyrate inhibited CRC cell cycle G1/S transition. Con, control; E. coli, Escherichia coli.CC BY-NC · PubMed Central
Figure 5 Roseburia intestinalis (R.i) and butyrate restrict MC38 orthotopic tumour growth by directly boosting CD8+ T cells. (A) Schematic diagram showing the experimental design and timeline of MC38 orthotopic model. (B) Representative MC38 rectum orthotopic tumour morphologies. (C) Tumour volume (mm3) and (D) tumour weight. (E) Proportion of tumour infiltrating CD8+ T cells in all nucleated cells of MC-38 orthotopic tumour tissues determined by immunohistochemistry. (F) Frequencies of granzyme B, interferon (IFN)-γ, tumour necrosis factor (TNF)-α within CD8+ populations of tumours from control, Escherichia coli-treated and R.i-treated C57BL/6J mice. (G) Frequencies of MDSC from tumour tissues in control, E. coli-treated and R.i-treated C57BL/6J mice measured by flow cytometry. Con, control; PD-1, programmed cell death protein 1.
Figure 5 Roseburia intestinalis (R.i) and butyrate restrict MC38 orthotopic tumour growth by directly boosting CD8+ T cells. (A) Schematic diagram showing the experimental design and timeline of MC38 orthotopic model. (B) Representative MC38 rectum orthotopic tumour morphologies. (C) Tumour volume (mm3) and (D) tumour weight. (E) Proportion of tumour infiltrating CD8+ T cells in all nucleated cells of MC-38 orthotopic tumour tissues determined by immunohistochemistry. (F) Frequencies of granzyme B, interferon (IFN)-γ, tumour necrosis factor (TNF)-α within CD8+ populations of tumours from control, Escherichia coli-treated and R.i-treated C57BL/6J mice. (G) Frequencies of MDSC from tumour tissues in control, E. coli-treated and R.i-treated C57BL/6J mice measured by flow cytometry. Con, control; PD-1, programmed cell death protein 1.CC BY-NC · PubMed Central
Figure 6 Roseburia intestinalis (R.i) and butyrate treatments are effective in CT26 orthotopic tumour via CD8+ T cells independently from antiprogrammed cell death protein 1 (anti-PD-1) therapy. (A) Schematic diagram showing the experimental design and timeline of CT26 orthotopic model. (B) Representative CT26 rectum orthotopic tumour morphologies. (C) Tumour volume (mm3) and (D) tumour weight. (E) Proportion of tumour infiltrating CD8+ T cells of CT-26 orthotopic tumour in all nucleated cells determined by immunohistochemistry. (F) Frequencies of granzyme B, interferon (IFN)-γ, tumour necrosis factor (TNF)-α within CD8+ populations of tumours from control, Escherichia coli-treated and R.i-treated BALB/c mice. (G) Frequencies of MDSC from tumour tissues in control, E. coli-treated and R.i-treated BALB/c mice measured by flow cytometry. Con, control.
Figure 6 Roseburia intestinalis (R.i) and butyrate treatments are effective in CT26 orthotopic tumour via CD8+ T cells independently from antiprogrammed cell death protein 1 (anti-PD-1) therapy. (A) Schematic diagram showing the experimental design and timeline of CT26 orthotopic model. (B) Representative CT26 rectum orthotopic tumour morphologies. (C) Tumour volume (mm3) and (D) tumour weight. (E) Proportion of tumour infiltrating CD8+ T cells of CT-26 orthotopic tumour in all nucleated cells determined by immunohistochemistry. (F) Frequencies of granzyme B, interferon (IFN)-γ, tumour necrosis factor (TNF)-α within CD8+ populations of tumours from control, Escherichia coli-treated and R.i-treated BALB/c mice. (G) Frequencies of MDSC from tumour tissues in control, E. coli-treated and R.i-treated BALB/c mice measured by flow cytometry. Con, control.CC BY-NC · PubMed Central
Figure 7 Comparable dosage of butyrate in Roseburia intestinalis cultured medium (R.i CM) suppresses colorectal cancer cells by direct CD8+ T cell boosting in vitro. (A) R.i CM directly boosted granzyme B+, interferon (IFN)-γ+, tumour necrosis factor (TNF)-α+ CD8+ T cells isolated from human peripheral blood mononuclear cells (PBMC). (B) The messenger RNA (mRNA) expression level of significant changed receptors on CD8+ T cells after treatment with R.i CM or (C) butyrate. (D) Binding affinity between toll-like receptor 5 (TLR5) and butyric acid was measured by surface plasmon resonance (left), affinity of TLR5 to butyric acid was 264 μM (right). (E) Representative structure of butyrate and TLR5 after molecular docking. The structure of TLR5 is represented in green and the butyrate is shown as stick in the centre (left). Relative interactions between butyrate and four amino acids of TLR5 generated by LigPlot (right). (F) Jurkat E6.1 T cell lysate incubation with anti-TLR5 or mouse IgG, together with or without 10 mM NaBu in pull-down buffer. Elute was evaluated by liquid chromatography-mass spectrometry (upper) and western blot analysis (down). (G) granzyme B+, IFN-γ+, TNF-α+ CD8+ T cells isolated from human PBMC were directly boosted by comparable dosage of butyrate and abolished by TLR5 antagonist TH1020. (H) Nuclear factor kappa B (NF-κB) (p65) nuclear translocation determined by NF-κB (p65) transcription factor assay. (I) Phospho-NF-κB p65 protein expression level of CD8+ T cells isolated from human PBMC after butyrate treatment with or without TH1020 inhibition. E. coli, Escherichia coli; YCFA, yeast casitone fatty acids broth. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
Figure 7 Comparable dosage of butyrate in Roseburia intestinalis cultured medium (R.i CM) suppresses colorectal cancer cells by direct CD8+ T cell boosting in vitro. (A) R.i CM directly boosted granzyme B+, interferon (IFN)-γ+, tumour necrosis factor (TNF)-α+ CD8+ T cells isolated from human peripheral blood mononuclear cells (PBMC). (B) The messenger RNA (mRNA) expression level of significant changed receptors on CD8+ T cells after treatment with R.i CM or (C) butyrate. (D) Binding affinity between toll-like receptor 5 (TLR5) and butyric acid was measured by surface plasmon resonance (left), affinity of TLR5 to butyric acid was 264 μM (right). (E) Representative structure of butyrate and TLR5 after molecular docking. The structure of TLR5 is represented in green and the butyrate is shown as stick in the centre (left). Relative interactions between butyrate and four amino acids of TLR5 generated by LigPlot (right). (F) Jurkat E6.1 T cell lysate incubation with anti-TLR5 or mouse IgG, together with or without 10 mM NaBu in pull-down buffer. Elute was evaluated by liquid chromatography-mass spectrometry (upper) and western blot analysis (down). (G) granzyme B+, IFN-γ+, TNF-α+ CD8+ T cells isolated from human PBMC were directly boosted by comparable dosage of butyrate and abolished by TLR5 antagonist TH1020. (H) Nuclear factor kappa B (NF-κB) (p65) nuclear translocation determined by NF-κB (p65) transcription factor assay. (I) Phospho-NF-κB p65 protein expression level of CD8+ T cells isolated from human PBMC after butyrate treatment with or without TH1020 inhibition. E. coli, Escherichia coli; YCFA, yeast casitone fatty acids broth. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 394

Metadata

Authors
Kang, X., Liu, C., Ding, Y., Ni, Y., Ji, F., Lau, H. C. H., Jiang, L., Sung, J. J., Wong, S. H., & Yu, J.
Affiliations
  • Chinese University of Hong Kong (HK)
  • Department of Anatomical and Cellular Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
  • Nanyang Technological University (SG)
Corresponding author
Yu, Jun
Venue
Gut
Publisher
BMJ
Published
2023-07-25
Volume
72
Issue
11
Pages
2112-2122
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4385232541
Cited by
394
References
38
Citations by year
2026: 144 · 2025: 178 · 2024: 68 · 2023: 4
FWCI
35.11
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DR-NTU (Nanyang Technological University) (submittedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Shenzhen-Hong Kong-Macao Science and Technology Program (Category C) Shenzhen (SGDX20210823103535016)
  • Centre for Microbiome Medicine and Wang Lee Wah Memorial Fund (Not Applicable, N/A)
  • Vice-Chancellor’s Discretionary Fund Chinese University of Hong Kong (4930775)
  • RGC Research Impact Fund Hong Kong (R4032-21F)
  • Research Talent Hub-Innovation and Technology Fund Hong Kong (ITS/177/21FP)
  • NTU Start Up Grant (021281-00001, 021337-00001)
  • Singapore Ministry of Health’s National Medical Research Council Clinician Scientist Individual Research Grant (MOH-CIRG23jan-0001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
Roseburia intestinalis, butyrate, colorectal cancer, anti-PD-1 therapy, CD8+ T cells, TLR5, NF-κB signaling, intestinal barrier, intestinal permeability, tight junctions, tumor immunology, probiotics, tumor microenvironment, microsatellite instability, ApcMin/+ mice
MeSH terms
Eubacteriales, Clostridiales, Animals, Butyrates, Cell Transformation, Neoplastic, Humans, Colorectal Neoplasms, CD8-Positive T-Lymphocytes, Mice, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8 + T cells. https://app.cochat.ai/papers/10.1136/gutjnl-2023-330291
The paper
Kang, X., Liu, C., Ding, Y., Ni, Y., Ji, F., Lau, H. C. H., Jiang, L., Sung, J. J., Wong, S. H., & Yu, J. (2023). Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8 + T cells. Gut. https://doi.org/10.1136/gutjnl-2023-330291

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.